Reuters Market Eye - Shares in Dr.Reddy's Laboratories up 1.2 percent after gaining 3.6 percent on Tuesday following the U.S. drug regulator's approval for selling a generic version of Celgene Corp's anti-cancer drug "Vidaza".
UBS raises Dr.Reddy's earnings estimates for FY14 and FY15 by 4 and 6 percent, respectively. It says, "First in class approvals like Vidaza and Dacogen and filing for Copaxone demonstrate Dr Reddy's strong capabilities in injectables space and focus on driving growth through niche products."
HSBC remains "overweight" but raises its target price on the stock to 2,660 rupees from 2,525 rupees. UBS maintains "buy" rating but raises its target price to 2,750 rupees from 2,600 rupees, citing higher estimates after the approval for generic Vidaza.
(Reporting by Abhishek Vishnoi)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app